Recognizing and treating secondary osteoporosis

  title={Recognizing and treating secondary osteoporosis},
  author={Karen Walker-Bone},
  journal={Nature Reviews Rheumatology},
  • K. Walker-Bone
  • Published 1 August 2012
  • Medicine
  • Nature Reviews Rheumatology
Osteoporosis, through its association with fragility fracture, is a major public health problem, costing an estimated $34.8 billion worldwide per annum. With projected demographic changes, the burden looks set to grow. Therefore, the prevention of osteoporosis, as well as its identification and treatment once established, are becoming increasingly important. Osteoporosis is secondary when a drug, disease or deficiency is the underlying cause. Glucocorticoids, hypogonadism, alcohol abuse and… 

Osteoporosis – a current view of pharmacological prevention and treatment

The current and future possibilities for identifying susceptible patients, from fracture risk assessment to shape modeling and in relation to the high heritability of osteoporosis are discussed, and the intimate relationship between the activities of bone forming and bone-resorbing cells is highlighted.

Osteoporosis in chronic inflammatory disease: the role of malnutrition

Possible causes of bone loss and fractures in subjects affected by chronic inflammatory disease and to suggest new targets for intervention are explored.

The molecular etiology and treatment of glucocorticoid-induced osteoporosis

The major therapeutic options approved for GIOP treatment include antiresorption drug bisphosphonates, parathyroid hormone N-terminal fragment teriparatide, and the monoclonal antibody denosumab.

Male Osteoporosis Secondary causes

HIV, whilst not being specific to men, is an increasingly recognised cause of male osteoporosis and the use of bisphosphonates and denosumab in this group of patients is worth considering.

Secondary osteoporosis and metabolic bone disease in patients 50 years and older with osteoporosis or with a recent clinical fracture: a clinical perspective

Calcium, phosphate, creatinine, albumin, erythrocyte sedimentation rate in all patients, 24 h urine calcium in men and serum testosterone in men less than 70 years are recommended.

Osteoporosis and malignancy: a dicey combination

A case emphasising that serious underlying illness can present with vertebral fractures and can be missed if other clues from clinical examination and investigations are overlooked is reported.


There is currently limited evidence regarding osteoporosis and osteopenia in premenopausal women, but the use of conservative strategies for co-managing secondary causes may have the potential to improve long-term management of these conditions.

Assessment of bone metabolism in premenopausal females with hyperthyroidism and hypothyroidism.

Hyperthyroidism poses a negative effect on bone metabolism in premenopausal females and hypothyroidism in pre menopausal females does not have any influence on bone density.

Glucocorticoids and Sarcoidosis: A Longitudinal Study on the Effects on Cortical and Trabecular Bone.

Treatment of initial mild sarcoidosis with dose tapered glucocorticoid therapy only mildly affects the final trabecular and cortical bone and hormone levels.

The Trabecular Bone Score (TBS) Complements DXA and the FRAX as a Fracture Risk Assessment Tool in Routine Clinical Practice

TBS enhances performance of the FRAX tool, where its greatest utility appears to lie in its ability to accurately classify those patients whose BMD level lies close to the intervention threshold, aiding in decisions on whether treatment is warranted or not.



AGA technical review on osteoporosis in gastrointestinal diseases.

Osteoporosis is increasingly recognized as a source of significant disability, an awareness that has prompted clinicians to actively pursue the diagnosis among high-risk patients, and much of the available clinical information regarding osteoporotic screening, outcomes, and therapeutic interventions is derived from the postmenopausal osteoporeosis literature.

Osteoporosis: impact on health and economics

Fracture incidence varies between populations, and is set to increase over coming decades as the global population becomes more elderly, particularly marked in the developing world, which is additionally assuming more-westernized lifestyles that predispose to increased fracture risk.

Approach to the patient with secondary osteoporosis.

Calcium and vitamin D supplementation should be initiated with doses that result in normocalcemia and serum 25-hydroxyvitamin D concentrations of at least 30 ng/ml, and Oral and i.v. bisphosphonates are effective and safe drugs for most forms of secondary osteoporosis.

Osteoporosis in men: the value of laboratory testing

A relatively modest evaluation of men with osteoporosis found many with undiagnosed secondary causes and multiple unrecognized risk factors, including hypogonadism, vitamin D deficiency, hypercalciuria, subclinical hyperthyroidism, and hyperparathyroidism.

Search for hidden secondary causes in postmenopausal women with osteoporosis

Objective: The prevalence of secondary processes in women with postmenopausal osteoporosis (OP) is not well known. The aim of this study was to analyze the prevalence of conditions contributing to

Secondary Osteoporosis in Men and Women: Clinical Challenge of an Unresolved Issue

The prevalence of secondary osteoporosis in men is similar to that in women and it is less frequent than commonly reported, which may provide an estimate of a particularly high fracture risk in patients whose bone fragility is usually attributed to another disease.

RANKL-Targeted Therapies: The Next Frontier in the Treatment of Male Osteoporosis

Denosumab, the only RANKL-targeted therapy currently available, increases bone mineral density and decreases fracture rate in men with prostate cancer and is also associated with delayed time to first skeletal-related event and an increase in bone metastasis-free survival in these men.

Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women.

Our purpose in this study was to determine the prevalence of undetected disorders of bone and mineral metabolism in women with osteoporosis and to identify the most useful and cost-efficient